
Anita Kambhampati, Centers for Disease Control and Prevention
Blanca Vargas, Michael E. DeBakey VA Medical Center
Mahwish Mushtaq, Michael E. DeBakey VA Medical Center
Hannah Browne, Centers for Disease Control and Prevention
Sara Perregaux, Centers for Disease Control and Prevention
Scott Grytdal, Centers for Disease Control and Prevention
Robert L Atmar, Baylor College of Medicine
Jan Vinje, Centers for Disease Control and Prevention
Umesh D. Parashar, Centers for Disease Control and Prevention
Aron J. Hall, Centers for Disease Control and Prevention

Only first 10 authors above; see publication for full author list.

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017-10-04, Pages S317-S317
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx163.741
Permanent URL: https://pid.emory.edu/ark:/25593/s6f7h

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.741

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed August 1, 2019 3:01 AM EDT
Conclusion. Vaccinated individuals were more likely than unvaccinated individuals to benefit from antiviral treatment. This finding warrants confirmation in other populations.


Nina Kambhampati, MPH1; Sara Perregaux, BS2; Scott Gryzal, MPH3; Robert L. Atmar, MD4; Jan Vinje, PhD5; Umesh D. Parashar, MBBS3; Jan Vinje, PhD5; Benjamin Lopez, PhD2; and Maria C. Rodriguez-Barradas, MD2.

Background. Norovirus is the leading cause of acute gastroenteritis (AGE) outbreaks in the United States; however, little data exist on the burden of endemic norovirus disease. Robust estimates of the norovirus disease burden among US adults are needed to inform assessment of potential norovirus vaccines, which are currently in development.

Methods. We conducted active surveillance for AGE at the Michael E. DeBakey VA Medical Center, Houston, Texas, by collecting stool specimens from AGE-coded outpatient encounters and inpatient visits and hospitalizations. The prevalence of norovirus among tested specimens by AGE-coded outpatient encounters and inpatient visits were calculated by multiplying the prevalence of AGE among tested specimens by the annual rate of AGE reported from VA Outpatient Clinics (OPCs) and Inpatient wards. Demographic data and illness characteristics were collected from enrolled subjects, and stool samples were collected and tested using the FilmArray gastrointestinal panel. Norovirus positive specimens were confirmed by real-time RT-PCR and genotyped after sequencing of conventional PCR products.

Results. From November 1, 2015–November 30, 2016, 130 inpatients and 85 outpatient AGE cases were partners, along with 20 inpatient and 37 outpatient controls were enrolled, and were provided a stool specimen. Among cases, 201 (93%) were male, and 94 (44%) were ≥65 years; median duration of illness was 3 days (range, 1–10 days). Norovirus was detected in 12 (9%) inpatients and 15 (18%) outpatient controls; norovirus was not detected in any controls. Incidence of norovirus-associated hospitalization was 15/100,000 population, and was similar in hospitalized cases aged <65 years (14/100,000) and ≥65 years (15/100,000). Nineteen (92%) patients without AGE symptoms in the prior 14 days were enrolled as controls. Demographic data and illness characteristics were collected from enrolled subjects, and stool samples were collected and tested using the FilmArray gastrointestinal panel. Norovirus positive specimens were confirmed by real-time RT-PCR and genotyped after sequencing of conventional PCR products.

Conclusion. This robust, active surveillance platform employed screening and enrollment of patients in a VA population meeting a standardized AGE case definition, as well as symptomatic controls. Data from this study will help to define the burden of norovirus in adults and importance of a norovirus vaccine.

Disclosures. R. L. Atmar, Takeda Vaccines, Inc.: Research Support, Research support. B. Lopman, HHS/NIAID: Grant Investigator, Grant recipient. Bill & Melinda Gates Foundation: Grant Investigator, Grant recipient.

1045. Norovirus, Astrovirus, and Sapovirus in a Tertiary Care Research Hospital, San Francisco, California, California at Los Angeles, Los Angeles, California, Section of Infectious Diseases, National Institutes of Health, Bethesda, Maryland, and Maria C. Rodriguez-Barradas, MD2.

Background. Norovirus, astrovirus, and sapovirus are known to cause acute gastroenteritis. We sequenced 300 sections with chronic viral excretion in stool among immuno-compromised patients. Because molecular tools for their detection only recently became widely available, the prevalence and chronic excretion of these viruses has not been well defined. We describe features of these viral infections among patients receiving care at the Clinical Center of the National Institutes of Health.

Methods. We identified patients with a positive BioFire FilmArray gastrointestinal panel report for norovirus, astrovirus, or sapovirus from September 15, 2015 through November 30, 2016. We reviewed patient medical records to abstract clinical and microbiologic information. Chronic excretion was defined as more than one positive test for a given virus with more than 30 days between tests.

Results. Of 932 samples tested, 102 (11%) samples from 48 patients tested positive for norovirus, 15 (2%) samples from 11 patients tested positive for sapovirus, and 16 (2%) samples from 7 patients tested positive for astrovirus. One of these patients had a sample that tested positive for both sapovirus and norovirus, and one tested positive for astrovirus and sapovirus at separate points during the study period. Of the 48 patients with norovirus, 16 (33%) had evidence of chronic excretion, with a median duration of 189 days (range 72–372). Of these 16, 14 were known or suspected to be immunodeficient, and 4 had hematologic malignancies. Of 7 patients with astrovirus, 1 (14%) had evidence of chronic excretion (132 days). This patient had a hematologic malignancy and was taking immunosuppressive medications. No patients with sapovirus had evidence of chronic excretion. Overall, 20 (31%) patients additionally tested positive for another gastrointestinal pathogen, most commonly enteropathogenic E. coli and C. difficile.

Conclusion. Norovirus remains common in this immunocompromised patient population, and both sapovirus and astrovirus are present. Additional follow-up in this and other cohorts with new molecular tools will enable more complete description of the prevalence, excretion duration, and clinical features of infection with these enteric viruses.

This research was supported by the Intramural Research Program of the NIH, NIAID, and the NIH CC.

Disclosures. All authors: No reported disclosures.

1046. Incidence of Norovirus-Associated Acute Gastroenteritis in Four Veteran’s Affairs Medical Center Populations in the United States, 2011–2015

Scott Gryzal, MPH1; Hannah Brown, BS2; Nikial Collins, BS3; Blanca Vargas, MD3, Maria Rodriguez-Barradas, MD3; David Beenhouwer, MD3; Sheldon Brown, MD2; Cynthia Lacero-Obusan, MD1; Mark Heleny, MD, FIDSA, FSHEA; Anita Kambhampati, MPH4; Umesh D. Parashar, MBBS3; Jan Vinje, PhD5; Benjamin Lopez, PhD2; and Cristi V. Cardemil, MD4.

Background. Norovirus is an important cause of epidemic acute gastroenteritis (AGE) as well as a leading cause of pediatric AGE. However, the burden of sporadic norovirus disease in US adults has not been well documented. Our objective was to estimate the incidence of outpatient visits and hospitalizations for community-acquired norovirus AGE at four Veterans Affairs Medical Centers (VAMCs) and their associated outpatient clinics in Atlanta, GA; Bronx, New York; Houston, TX; and Los Angeles, CA.

Methods. From November 2011 to September 2015, stool specimens collected for clinician-requested diagnostic testing within 7 days of AGE symptom onset were tested for norovirus by real-time RT-PCR and positive samples were genotyped by Sanger sequencing. Incidence of norovirus-associated outpatient visits and hospitalizations were calculated by multiplying the prevalence of norovirus among tested specimens by AGE-coded outpatient encounters and inpatient discharges, and dividing by the unique patients served at each VAMC.

Results. 1,620 stool specimens were tested from all 4 sites. Seven percent of outpatient (n = 795) samples (annual range: 3%–10%; range by site: 3%–10%) and 6% of inpatient (n = 825) samples from hospitalized patients tested positive for norovirus (annual range: 3%–8%; range by site: 3%–10%). Forty-four percent of norovirus-positive specimens were typed as GIL 4 Sydney. Seventy-four percent of norovirus-positive specimens were collected between November and April. From 2011 to 2015, the incidence of norovirus positivity and hospitalizations was calculated by multiplying the prevalence of norovirus among tested specimens by AGE-coded outpatient encounters and inpatient discharges, and dividing by the unique patients served at each VAMC.

Conclusion. The present study provides estimates of the incidence of norovirus AGE outpatient visits and hospitalizations across multiple years among a geographically distributed VA population, highlighting the substantial burden of norovirus in US adults.

Disclosures. All authors: No reported disclosures.

1047. WU Polyomavirus Associated with Severe Respiratory Failure in Children

Kazuhiko Uda, MD1; Jan Vinje, PhD2; Sara Perregaux, BS1; Robert A. Atmar, MD3; Blanca Vargas, MD4; Sara Taskwa-Koyama, PSc1; and Isao Miyairi, MD4.

Background. WU polyomavirus (WUVPyV) is a recently discovered virus associated with respiratory infections. However, its role is unclear in children with severe pneumonia.